BIOMIRA develops synthetic vaccines that boost the immune system against cancer without the damaging effects of radiation or chemotherapy. Lead product candidate Theratope is a possible vaccine for metastatic breast cancer that has received fast-track designation from the FDA. The drug is also in clinical trials as a possible treatment for metastatic colorectal cancer. BLP-25, a potential lung and prostate cancer vaccine. Biomira expanded its oncology pipeline with the 2006 acquisition of privately held ProIX Pharmaceuticals.